Novo Nordisk’s Worst Year Might Be Your Best Entry Point

Danish pharma giant Novo Nordisk A/S (ticker NVO) may be enduring its toughest year yet, but that slump could spell opportunity. According to a recent analysis, 2025 may represent the “peak pain” for Novo, with a sharp share‑price drop having potentially overshot the company’s underlying fundamentals. Despite the turbulence—marked by guidance cuts and pricing pressure—the author argues Novo’s core business remains intact. Restructuring charges are clouding current profitability, while major catalysts like a forthcoming oral version of its blockbuster weight‑loss drug Wegovy and a 2026 filing for its next‑gen candidate CagriSema are viewed as drivers for a rebound. On valuation, the article estimates a 12‑month price target of around $56.30, implying upside of 14‑15% if cost savings and pipeline execution play out. Bottom line: if you’re a long‑term investor with tolerance for risk, this could be a “growth at a reasonable price” moment (GARP) for Novo Nordisk. That said, the usual caveats apply—pipeline execution, competitive pressures, and pricing regulation all remain potential headwinds. #NovoNordisk #GLP1drugs #PharmaInvesting #ValueOpportunity #SlimScan #GrowthStocks #CANSLIM